Hemophilia A Market Gains Momentum with Expanding Pipeline and Investment Potential - DelveInsight

DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hemophilia A market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia A Market Forecast
https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hemophilia A Market Report:
• The Hemophilia A market size across the 7MM was valued at approximately USD 12,918 million in 2025 and is anticipated to reach nearly USD 16,756 million by 2034, expanding at a CAGR of 2.9% across major markets, including the US, EU4, the UK, and Japan.
• In 2024, the United States accounted for the largest Hemophilia A market size among the 7MM, reaching nearly USD 5,920 million, with continued growth anticipated through 2034.
• In 2024, the Hemophilia A market size in Japan was estimated at approximately USD 1,150 million and is projected to witness growth throughout the forecast period from 2025 to 2034.
• In April 2026, The New England Journal of Medicine published 26-week findings from the Phase III FRONTIER2 trial assessing the efficacy and safety of once-monthly and once-weekly Denecimig in adults and adolescents aged 12 years and older with Hemophilia A, regardless of the presence of FVIII inhibitors. Investigational denecimig is a bispecific antibody that mimics activated Factor VIII (FVIIIa) and is designed as a routine prophylactic therapy to support blood clot formation. The therapy is currently being evaluated through the FRONTIER clinical program across multiple dosing schedules, patient age groups, and disease severities in individuals with hemophilia A, both with and without inhibitors.
• In March 2026, Belief BioMed (BBM) and Grand Life Sciences Group Co., Ltd. have announced an exclusive collaboration agreement. Under this partnership, Belief BioMed will grant Grand Life Sciences commercialization rights for its investigational therapy, BBM-H803, across Mainland China, Hong Kong, Macau, and Taiwan. The agreement reflects both companies' commitment to combining their expertise and resources to accelerate the product's commercialization, expand access to innovative treatments for hemophilia A patients, and support the advancement of the gene therapy sector. The agreement was formalized by Xiao Xiao, Co-founder, Chairman, and CSO of Belief BioMed, and Zenghui Feng, Chairman of Grand Life Sciences.
• In May 2025, the FDA approved Jivi (antihemophilic factor [recombinant], PEGylated-aucl; Bayer) for treating pediatric patients aged 7 and older with hemophilia A, as announced by Bayer.
• In May 2025, the FDA approved Antihemophilic factor (recombinant), PEGylated-aucl (Jivi; Bayer) for treating pediatric patients aged 7 and older with hemophilia A. The approval was supported by results from the Alfa-PROTECT and PROTECT Kids trials.
• In April 2025, the FDA approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A or B, with or without factor VIII or IX inhibitors.
• In March 2025, the US FDA approved QFITLIA (fitusiran) as the first antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (12 years and older) with hemophilia A or B, with or without factor VIII or IX inhibitors.
• In March 2025, Alnylam Pharmaceuticals announced the FDA's approval of QfitliaTM (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S. It is the first and only treatment to lower antithrombin (AT), aiming to promote thrombin generation, rebalance hemostasis, and prevent bleeds.
• In October 2024, Pfizer Inc. announced FDA approval for HYMPAVZITM (marstacimab-hncq) as a routine prophylactic treatment for adults and pediatric patients aged 12 and older with Hemophilia A or B, excluding those with FVIII or FIX inhibitors.
• The epidemiology segment also provides the Hemophilia A epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The total diagnosed prevalent population of Hemophilia A in the 7MM comprised nearly 49,500 cases in 2024 and is projected to increase during the forecast period.
• The total diagnosed prevalent population of Hemophilia A in the United States was nearly 14,900 in 2024.
• EU4 and the UK contributed to the largest prevalent population of Hemophilia A, accounting for ~58% of the 7MM in 2024.
• In EU4 and the UK, the diagnosed prevalence of Hemophilia A was found to be maximum in France, followed by the UK. While the least number of cases were found in Spain in 2024.
• In 2024, the prevalent cases of mild Hemophilia A in the United States were identified to be ~35%, moderate as ~15%, and severe as ~50%.
• In the US, nearly 2,000 cases accounted for inhibitors and ~12,700 cases for non-inhibitors in 2024.
• Key Hemophilia A Companies: BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, CSL Behring, Novo Nordisk A/S, Bayer, Takeda, Sanofi, Biocad, Green Cross Corporation, Hoffmann-La Roche, Bayer, Spark Therapeutics, ASC Therapeutics, Hoffmann-La Roche, Shir, Carelon Research, and others
• Key Hemophilia A Therapies: rVIII-SingleChain, NNC0365-3769 (Mim8) PPX, Recombinant Factor VIII (Kovaltry, BAY81-8973), Adynovate, efanesoctocog alfa (BIVV001), ANB-010, GreenGene, NXT007, BAY2599023 (DTX201), SPK-8011, ASC618, Emicizumab, BAX 888, Rituximab, and others
• The Hemophilia A market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia A pipeline products will significantly revolutionize the Hemophilia A market dynamics.

Hemophilia A Overview
Hemophilia A is a genetic disorder that affects blood clotting. It is characterized by a deficiency or dysfunction of clotting factor VIII, which plays a crucial role in the blood coagulation process. Hemophilia A is the most common type of hemophilia, and it is also known as classic hemophilia.

Get a Free sample for the Hemophilia A Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia A Epidemiology
The Hemophilia A epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia A Epidemiology Segmentation:
The Hemophilia A market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM countries is segmented into:
• Total Prevalence of Hemophilia A
• Prevalent Cases of Hemophilia A by severity
• Gender-specific Prevalence of Hemophilia A
• Diagnosed Cases of Episodic and Chronic Hemophilia A

Download the report to understand which factors are driving Hemophilia A epidemiology trends @ Hemophilia A Epidemiology Forecast
https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia A Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia A market or expected to get launched during the study period. The analysis covers Hemophilia A market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hemophilia A Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hemophilia A Therapies and Key Companies
• ROCTAVIAN (valoctocogene roxaparvovec): BioMarin Pharmaceutical
• Mim8: Novo Nordisk
• Peboctocogene camaparvovec (DTX201 or BAY2599023): Ultragenyx Pharmaceutical
• rVIII-SingleChain: CSL Behring
• NNC0365-3769 (Mim8) PPX: Novo Nordisk A/S
• Recombinant Factor VIII (Kovaltry, BAY81-8973): Bayer
• Adynovate: Takeda
• efanesoctocog alfa (BIVV001): Sanofi
• ANB-010: Biocad
• GreenGene: Green Cross Corporation
• NXT007: Hoffmann-La Roche
• BAY2599023 (DTX201): Bayer
• SPK-8011: Spark Therapeutics
• ASC618: ASC Therapeutics
• Emicizumab: Hoffmann-La Roche
• BAX 888: Shire
• Rituximab: Carelon Research

Discover more about therapies set to grab major Hemophilia A market share @ Hemophilia A Treatment Landscape
https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Hemophilia A Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hemophilia A Companies: BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, =CSL Behring, Novo Nordisk A/S, Bayer, Takeda, Sanofi, Biocad, Green Cross Corporation, Hoffmann-La Roche, Bayer, Spark Therapeutics, ASC Therapeutics, Hoffmann-La Roche, Shir, Carelon Research, and others
• Key Hemophilia A Therapies: rVIII-SingleChain, NNC0365-3769 (Mim8) PPX, Recombinant Factor VIII (Kovaltry, BAY81-8973), Adynovate, efanesoctocog alfa (BIVV001), ANB-010, GreenGene, NXT007, BAY2599023 (DTX201), SPK-8011, ASC618, Emicizumab, BAX 888, Rituximab, and others
• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hemophilia A Unmet Needs, KOL's views, Analyst's views, Hemophilia A Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.